Clinical Trials Logo

Clinical Trial Summary

The goal of this study is to visualize the deposition of topical 0.3% roflumilast (Zoryve) compared to vehicle using Line-Field Optical Coherence Tomography (LC-OCT) in vivo in healthy skin. We hypothesize that the application of topical 0.3% roflumilast (Zoryve) will result in distinct patterns of deposition within the epidermal and dermal layers compared to the vehicle. Specifically, we anticipate observing deeper penetration and more uniform distribution of roflumilast within the skin layers, indicative of enhanced efficacy, as visualized by LC-OCT imaging.


Clinical Trial Description

Primary Objective Compare the deposition of Zoryve and the vehicle in the epidermal and dermal layers using LC-OCT. Primary Endpoint The primary endpoint of this study is a visual qualitative analysis of LC-OCT images conducted by an expert confocalist, Babar Rao MD. This analysis aims to assess the penetration of the active drug product compared to the vehicle. Subjects will be instructed to apply topical 0.3% Zoryve once daily for seven consecutive days to a predetermined 2x2cm area on the dorsal surface forearm, as defined by the investigator. Additionally, participants will apply a topical cream vehicle provided by Zoryve to the dorsall side of the opposite forearm. Therefore, one forearm, will be designated for application of Zoryve, while the other forearm will the designated for application of the topical cream vehicle supplied by Zoryve. Subjects will apply the topical vehicle and roflumilast, daily, for 7 consecutive days. LC-OCT imaging will be conducted on both arms at various time points: baseline (T0A), 15 minutes (T0B), 1 hour (T0C), 8-12 hours (T0D), 24 hours (T0E), seven days after application (T7), and seven days after not applying cream (T14). LC-OCT imaging will follow a predefined image acquisition protocol, with investigators designating 2x2cm areas for imaging. The imaging protocol will include capturing 2D vertical photos, 3D photos, and 2D vertical videos per imaging site. Participants will be instructed to photograph the imaging sites to aid in the accurate application of the active drug product or vehicle cream base. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06440473
Study type Interventional
Source Rao Dermatology
Contact Bassem Rafiq, BS
Phone 2403974368
Email Rafiqbassem@gmail.com
Status Recruiting
Phase Phase 4
Start date May 28, 2024
Completion date July 28, 2024

See also
  Status Clinical Trial Phase
Completed NCT01951391 - Effect of Surfactants on the Skin Microbiome N/A
Completed NCT00111254 - The Effects of Microdermabrasion on Skin Remodeling N/A
Completed NCT04406454 - The Application of Non-invasive and Cellular Level Resolution Fullfield Optical Coherence Tomography: Establishment and Analysis of Subcutaneous Cellular Level Image Database of Anatomical Locations in Healthy Volunteers and Evaluation of Usability
Completed NCT03625167 - Effect of a Basic Skin Care Product on the Structural Strength of the Skin N/A
Completed NCT01552135 - Pilot Study - Putative Penetration of Nanoparticles in Sunscreen in Intact or Sunburned Skin
Completed NCT00971282 - Adjunctive Usage of a Moisturizing Lotion (Cetaphil® Moisturizing Lotion) to Limit the Skin Irritation Linked to the Set-Up of a Treatment by Topical Retinoid (Differin® Gel 0,1%) in Healthy Subjects of Chinese Origins Phase 4